- Conditions: Cannabis Dependence; Marijuana Dependence
Interventions: Drug: Dronabinol; Drug: Clonidine; Drug: Placebo
Sponsors: Mclean Hospital; Mclean Hospital; Brain and Behavior Research Foundation (formerly NARSAD)
Recruiting - verified May 2012 - Conditions: Pain, Postoperative; Postoperative Nausea and Vomiting
Interventions: Drug: Tumescent solution with dilute lidocaine and epinephrine; Drug: Tumescent Solution with dilute epinephrine
Sponsors: University of Wisconsin, Madison; University of Wisconsin, Madison
Not yet recruiting - verified May 2012 - Condition: Stress Urinary Incontinence
Interventions: Drug: Bupivicaine + epinephrine; Drug: Sodium chloride + epinephrine
Sponsors: University of Massachusetts, Worcester; University of Massachusetts, Worcester
Recruiting - verified April 2012 - Condition: Pain
Intervention: Drug: 3% mepivacaine/2% lidocaine with 1:100,000 epinephrine combo
Sponsors: Ohio State University; Ohio State University
Not yet recruiting - verified April 2012 - Condition: Subarachnoid Hemorrhage, Aneurysmal
Interventions: Drug: Dexmedetomidine; Drug: propofol
Sponsors: University of Cincinnati; University of Cincinnati
Recruiting - verified March 2012 - Conditions: Tourette Disorder; Tourette Syndrome
Interventions: Drug: placebo; Drug: extended-release guanfacine (Intuniv)
Sponsors: Yale University; Yale University; New York University; University of South Florida; Shire Development LLC
Recruiting - verified May 2012 - Condition: Radiodermatitis
Intervention: Drug: Norepinephrine
Sponsors: ProCertus BioPharm, Inc; ProCertus BioPharm, Inc; H. Lee Moffitt Cancer Center and Research Institute
Recruiting - verified March 2012 - Conditions: Postoperative Pain; Paracervical Block; Laparoscopic Gynecologic Surgery
Interventions: Drug: Bupivacaine with epinephrine; Drug: Normal Saline
Sponsors: Mount Sinai School of Medicine; Mount Sinai School of Medicine
Recruiting - verified February 2012 - Conditions: Hot Flashes; Breast Cancer
Interventions: Drug: solifenacin; Drug: Clonidine
Sponsors: University of Arkansas; University of Arkansas
Recruiting - verified February 2012 - Condition: Tonsillectomy
Interventions: Drug: Dexmedetomidine; Other: Placebo
Sponsors: Children's Hospital of Pittsburgh; Children's Hospital of Pittsburgh; Hospira, Inc.
Recruiting - verified February 2012 - Conditions: Glaucoma; Ocular Hypertension
Interventions: Drug: 0.1% brimonidine tartrate and 0.01% bimatoprost; Drug: 0.01% bimatoprost and 0.2% hypromellose
Sponsors: Allergan; Allergan
Recruiting - verified January 2012 - Conditions: Ultrasound; CT Scans; MRIs
Interventions: Drug: Dexmedetomidine; Drug: Midazolam; Drug: Fentanyl
Sponsors: Hospira, Inc.; Hospira, Inc.
Recruiting - verified April 2012 - Condition: Glaucoma
Intervention: Drug: Brinzolamide/Timolol Maleate Fixed Combination (AZARGA)
Sponsors: Alcon Research; Alcon Research
Recruiting - verified January 2012 - Condition: Myringotomy
Intervention: Drug: Dexmedetomidine
Sponsors: University of Iowa; University of Iowa
Recruiting - verified February 2012 - Condition: Anesthesia
Interventions: Drug: Midazolam; Drug: Fentanyl; Drug: Morphine
Sponsors: Hospira, Inc.; Hospira, Inc.
Recruiting - verified April 2012 - Conditions: Overactive Bladder; Overactive Urinary Bladder
Interventions: Drug: MK-4618; Drug: Tolterodine ER; Drug: MK-1468 and Tolterodine ER; Other: Placebo (MK-4618); Other: Placebo (Tolterodine ER); Drug: Prophylactic Antibiotic
Sponsors: Merck; Merck
Recruiting - verified February 2012 - Conditions: Tethered Spinal Cord; Brain Tumor; Cranio Cervical Compression
Intervention: Other: Isoflurane, Propofol, Dexmedetomidine
Sponsors: Oregon Health and Science University; Oregon Health and Science University
Recruiting - verified January 2012 - Conditions: Neonatal Neurobehavior; Breastfeeding Outcomes
Interventions: Drug: Bolus 10mL 0.25% bupivacaine/ep 1:600,000; infusion 10mL/hour 0.25% bupivacaine and epi 1:800,000; Drug: Bolus 10mL 0.25% bupivacaine/ epinephrine 1:600,000;infusion 10mL/hour 0.25% bupivacaine, 2 mcg/mL fentanyl, and epinephrine 1:800,000; Drug: Bolus 10mL 0.25% bupivacaine, 10mcg/mL fentanyl, and epi 1:600,000; infusion 10mL/hour 0.25% bupivacaine, 2.5 mcg/mL fentanyl, and epi 1:800,000; Drug: Bolus 10mL 0.25% bupivacaine, 5 mcg/mL fentanyl, and epi 1:600,000; infusion 10mL/hour 0.25% bupivacaine, 3.5 mcg/mL fentanyl, and epi 1:800,000; Drug: No epidural fentanyl or bupivacaine
Sponsors: University Hospital Case Medical Center; University Hospital Case Medical Center
Not yet recruiting - verified April 2012 - Condition: Supraventricular Tachycardia
Interventions: Drug: Dexmedetomidine; Drug: Adenosine
Sponsors: University of Pittsburgh; University of Pittsburgh
Recruiting - verified February 2012 - Condition: Insomnia
Interventions: Drug: Dexmedetomidine; Drug: Zolpidem; Drug: Oral Placebo; Drug: Normal Saline placebo.
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital; National Institutes of Health (NIH)
Recruiting - verified December 2011 - Condition: Dexmedetomidine Induced Sedation
Intervention: Drug: dexmedetomidine
Sponsors: Massachusetts General Hospital; Massachusetts General Hospital
Recruiting - verified April 2012 - Condition: Asthma
Interventions: Drug: Placebo; Drug: Primatene Mist; Drug: Epinephrine inhalation aerosol, HFA; Drug: epinephrine inhalation aerosol
Sponsors: Amphastar Pharmaceuticals, Inc.; Amphastar Pharmaceuticals, Inc.
Recruiting - verified November 2011 - Conditions: Generalized Anxiety Disorder (GAD); Anxiety, Separation; Phobia, Social
Interventions: Drug: SPD503 (extended-release Guanfacine hydrochloride); Drug: Placebo
Sponsors: Shire Development LLC; Shire Development LLC
Recruiting - verified April 2012 - Condition: Cannabis Dependence
Intervention: Drug: Guanfacine
Sponsors: New York State Psychiatric Institute; New York State Psychiatric Institute
Not yet recruiting - verified December 2011 - Condition: Asthma
Intervention: Drug: Epinephrine Inhalation Aerosol
Sponsors: Amphastar Pharmaceuticals, Inc.; Amphastar Pharmaceuticals, Inc.
Recruiting - verified October 2011 - Condition: Hypertension
Interventions: Drug: Para-aminohippuric Acid; Drug: Angiotensin II; Drug: Norepinephrine
Sponsors: Brigham and Women's Hospital; Brigham and Women's Hospital; National Heart, Lung, and Blood Institute (NHLBI); National Institutes of Health (NIH)
Recruiting - verified April 2012 - Conditions: Hypertension; Insulin Resistance
Interventions: Drug: Para-aminohippuric Acid; Drug: Angiotensin II; Drug: Norepinephrine
Sponsors: Brigham and Women's Hospital; Brigham and Women's Hospital; National Heart, Lung, and Blood Institute (NHLBI); National Institutes of Health (NIH)
Recruiting - verified May 2012 - Condition: Uterine Cervical Dysplasia
Intervention: Drug: sodium bicarbonate buffered lidocaine
Sponsors: Washington University School of Medicine; Washington University School of Medicine
Recruiting - verified October 2011 - Condition: Airway Remodeling
Interventions: Drug: Dexmedetomidine; Drug: propofol
Sponsors: Milton S. Hershey Medical Center; Milton S. Hershey Medical Center
Not yet recruiting - verified January 2012 - Condition: Sialorrhoea
Interventions: Drug: OC oral solution treatment A; Drug: OC oral solution treatment B; Drug: OC oral solution treatment C; Drug: OC oral solution treatment D
Sponsors: Orient Pharma Co., Ltd.; Orient Pharma Co., Ltd.
Recruiting - verified May 2012 - Condition: Chronic Rhinitis
Interventions: Drug: Placebo; Drug: Guaifenesin
Sponsors: Virginia Commonwealth University; Virginia Commonwealth University; Pfizer
Recruiting - verified May 2011 - Conditions: Orthostatic Hypotension; Pure Autonomic Failure; Multiple System Atrophy; Parkinson's Disease
Intervention:
Sponsors: Vanderbilt University; Vanderbilt University; National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting - verified May 2012 - Condition: Urinary Bladder, Overactive
Interventions: Drug: MK-4618 low-dose; Drug: MK-4618 mid-low dose; Drug: MK-4618 mid-high dose; Drug: tolterodine ER; Drug: Placebo for MK-4618; Drug: Placebo for tolterodine ER; Drug: MK-4618 high dose
Sponsors: Merck; Merck
Recruiting - verified May 2012 - Conditions: Brain Injuries; Craniocerebral Trauma; Trauma, Nervous System; Traumatic Brain Injury
Interventions: Drug: IV Propranolol and Per Tube Clonidine; Drug: Placebo
Sponsors: Vanderbilt University; Vanderbilt University
Recruiting - verified March 2012 - Conditions: Open-angle Glaucoma; Ocular Hypertension
Interventions: Drug: Brinzolamide 1% / brimonidine 0.2% ophthalmic suspension; Drug: Brinzolamide 1% Eye drops, suspension BID (AZOPT); Drug: Brimonidine Tartrate
Sponsors: Alcon Research; Alcon Research
Recruiting - verified November 2011 - Condition: Open-angle Glaucoma or Ocular Hypertension
Interventions: Drug: Brinzolamide 1% / brimonidine 0.2% ophthalmic suspension; Other: Vehicle for masking purposes; Drug: Brinzolamide 1% ophthalmic suspension (AZOPT); Drug: Brimonidine 0.2% ophthalmic solution
Sponsors: Alcon Research; Alcon Research
Recruiting - verified November 2011 - Condition: Overactive Bladder
Interventions: Drug: Tolterodine ER; Drug: Placebo
Sponsors: Pfizer; Pfizer
Recruiting - verified May 2012 - Condition: Orthostatic Hypertension
Intervention: Drug: Intravenous Norepinephrine Infusion
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting - verified November 2011 - Conditions: Spinal Stenosis; Inflammation
Intervention:
Sponsors: New York University School of Medicine; New York University School of Medicine; Hospira, Inc.
Recruiting - verified April 2012 - Conditions: Adult Intracranial Tumor; Adult Solid Tumor
Interventions: Drug: Remifentanil; Drug: Dexmedetomidine
Sponsors: Outcomes Research Consortium; Outcomes Research Consortium
Recruiting - verified August 2011 - Condition: Radiodermatitis
Intervention: Drug: Norepinephrine
Sponsors: ProCertus BioPharm, Inc; ProCertus BioPharm, Inc; University of Wisconsin, Madison
Recruiting - verified January 2012 - Condition: Sleep Disorders
Interventions: Other: Normal saline infusion; Drug: Dexmedetomidine; Drug: Propofol
Sponsors: University of California, San Francisco; University of California, San Francisco; Masimo Labs
Recruiting - verified May 2012 - Condition: Attention Deficit Hyperactivity Disorder
Interventions: Drug: Extended-release Guanfacine Hydrochloride; Drug: Atomoxetine Hydrochloride; Drug: Placebo Comparator
Sponsors: Shire Development LLC; Shire Development LLC
Recruiting - verified May 2012 - Condition: Pervasive Development Disorders
Interventions: Drug: extended-release guanfacine; Other: placebo
Sponsors: Yale University; Yale University; Massachusetts General Hospital; Seattle Children's Hospital; University of California, Los Angeles; National Institute of Mental Health (NIMH)
Recruiting - verified May 2012 - Conditions: Deep Brain Stimulation (DBS); Blood Flow; Brain Oxygenation
Interventions: Drug: dexmedetomidine; Drug: propofol
Sponsors: Outcomes Research Consortium; Outcomes Research Consortium
Recruiting - verified June 2011 - Condition: Interstitial Cystitis
Interventions: Drug: Dexmedetomidine; Drug: Normal Saline
Sponsors: University of Rochester; University of Rochester
Recruiting - verified August 2011 - Conditions: Opioid Related Disorders; Opioid Dependence; Opioid Addiction
Interventions: Drug: Buprenorphine/naloxone; Drug: Clonidine; Drug: Tramadol ER
Sponsors: National Institute on Drug Abuse (NIDA); National Institute on Drug Abuse (NIDA)
Recruiting - verified April 2012 - Condition: Treatment Refractory Depression
Interventions: Drug: Ketamine; Drug: Clonidine; Drug: placebo
Sponsors: Washington University School of Medicine; Washington University School of Medicine; University of Miami
Not yet recruiting - verified March 2012 - Condition: Neonatal Abstinence Syndrome
Interventions: Drug: Clonidine; Drug: Phenobarbital
Sponsors: Baystate Medical Center; Baystate Medical Center
Recruiting - verified April 2012 - Condition: Major Depressive Disorder
Intervention: Drug: Lisdexamfetamine Dimesylate 20-50 mg
Sponsors: Mclean Hospital; Mclean Hospital; Shire Development LLC
Recruiting - verified March 2012 - Condition: Attention-deficit/Hyperactivity Disorder
Intervention: Drug: Guanfacine (sustained release)
Sponsors: Neurology Group of Bergen County, P.A.; Neurology Group of Bergen County, P.A.; Shire Development LLC
Recruiting - verified July 2011 - Condition: Delirium
Interventions: Drug: Clonidine; Drug: Placebo
Sponsors: Memorial Health University Medical Center; Memorial Health University Medical Center
Recruiting - verified August 2011 - Conditions: Attention Deficit Hyperactivity Disorder; Reading Difficulty or Disability
Interventions: Drug: Methylphenidate; Behavioral: Intensive reading instruction; Behavioral: Parent Training; Drug: Mixed Salt Amphetamine; Drug: Atomoxetine; Drug: Guanfacine
Sponsors: The University of Texas Health Science Center, Houston; The University of Texas Health Science Center, Houston; Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Recruiting - verified February 2012 - Conditions: Alcohol Withdrawal Delirium; Alcohol Withdrawal Associated Autonomic Hyperactivity; Alcohol Withdrawal Hallucinosis; Alcohol Withdrawal-Induced Delirium Tremens
Interventions: Drug: Dexmedetomidine; Drug: Placebo
Sponsors: Denver Health and Hospital Authority; Denver Health and Hospital Authority
Recruiting - verified April 2012 - Condition: Seizure Disorders
Intervention: Drug: Dexmedetomidine
Sponsors: University of California, San Francisco; University of California, San Francisco
Recruiting - verified June 2011 - Condition: Pain
Interventions: Drug: Placebo administration; Drug: Dexmedetomidine administration
Sponsors: Northwestern University; Northwestern University
Recruiting - verified February 2012 - Condition: Glaucoma
Intervention: Drug: Alphagan (brimonidine) 0.15%
Sponsors: Massachusetts Eye and Ear Infirmary; Massachusetts Eye and Ear Infirmary
Recruiting - verified April 2012 - Condition: Cardiovascular Disease
Interventions: Drug: Active Clonidine; Drug: Placebo Clonidine; Drug: Active ASA; Drug: Placebo ASA
Sponsors: McMaster University; Hamilton Health Sciences Corporation; McMaster University
Recruiting - verified December 2011 - Condition: Attention-Deficit/Hyperactivity Disorder
Interventions: Drug: Extended-release Guanfacine Hydrochloride; Other: Placebo
Sponsors: Shire Development LLC; Shire Development LLC
Recruiting - verified May 2012 - Condition: Attention-deficit/Hyperactivity Disorder
Interventions: Drug: Extended-release Guanfacine Hydrochloride; Other: Placebo
Sponsors: Shire Development LLC; Shire Development LLC
Recruiting - verified December 2011 - Condition: Pulmonary Hypertension
Intervention: Drug: Dexmedetomidine
Sponsors: Children's Hospital of Philadelphia; Aruna Nathan; Children's Hospital of Philadelphia
Recruiting - verified May 2012 - Condition: Drug Dependence
Intervention: Drug: 2-4 of the drugs listed below
Sponsors: University of Arkansas; University of Arkansas; National Institute on Drug Abuse (NIDA)
Recruiting - verified February 2012 - Conditions: Cannabis Dependence; Marijuana Dependence
Interventions: Drug: Lofexidine and Dronabinol; Drug: Placebo
Sponsors: New York State Psychiatric Institute; New York State Psychiatric Institute; National Institute on Drug Abuse (NIDA)
Recruiting - verified April 2012 - Condition: Ambulatory Surgery
Interventions: Drug: Dexmedetomidine infusion; Drug: propofol
Sponsors: University of Medicine and Dentistry New Jersey; University of Medicine and Dentistry New Jersey
Recruiting - verified August 2011 - Condition: Lower Urinary Tract Symptoms
Interventions: Drug: dutasteride 0.5 mg, used with tolterodine ER 4mg or placebo; Drug: dutasteride
Sponsors: Siami, Paul F., M.D.; Siami, Paul F., M.D.; GlaxoSmithKline; Pfizer
Recruiting - verified July 2011 - Conditions: Anaphylaxis; Hypotension; Bronchospasm; Angioedema
Interventions: Drug: Epinephrine; Procedure: Bone Marrow Apsiration; Drug: Omalizumab (Xolair)
Sponsors: National Institutes of Health Clinical Center (CC); National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified December 2011 - Condition: Vascular Sensitivity
Intervention: Drug: phenylephrine and nitroglycerin
Sponsors: Vanderbilt University; Vanderbilt University
Recruiting - verified April 2012 - Conditions: Orthostatic Hypotension; Spinal Cord Injury
Interventions: Drug: L-NAME; Drug: Midodrine Hydrochloride
Sponsors: Department of Veterans Affairs; Department of Veterans Affairs
Recruiting - verified December 2011 - Condition: Otitis Media
Interventions: Drug: dexmedetomidine; Drug: saline
Sponsors: Ochsner Health System; Ochsner Health System
Recruiting - verified October 2011 - Condition: Smoking
Interventions: Drug: guanfacine; Drug: placebo
Sponsors: Yale University; Yale University
Recruiting - verified January 2012 - Condition: Ventricular Tachycardia
Interventions: Drug: clonidine; Drug: metoprolol
Sponsors: University of Iowa; University of Iowa; National Center for Research Resources (NCRR)
Recruiting - verified December 2007 - Conditions: Autonomic Nervous System Diseases; Orthostatic Hypotension
Interventions: Drug: droxidopa; Drug: placebo; Drug: alpha-methyldopa; Drug: carbidopa; Drug: metyrosine; Drug: levodopa; Drug: atomoxetine; Drug: metoclopramide
Sponsors: Vanderbilt University; Vanderbilt University
Recruiting - verified March 2012 - Conditions: Cocaine Dependent; Alcohol Dependent
Interventions: Drug: Guanfacine; Drug: Placebo
Sponsors: Yale University; Yale University; National Institute on Drug Abuse (NIDA)
Recruiting - verified March 2012 - Conditions: Chronic Fatigue Syndrome; Orthostatic Intolerance; Postural Tachycardia Syndrome
Interventions: Other: Autonomic Function Testing; Other: Saline infusions; Drug: L-NMMA trimethaphan; Drug: methyldopa
Sponsors: Vanderbilt University; Vanderbilt University
Recruiting - verified May 2012 - Conditions: Postoperative Delirium; PD; Postoperative Cognitive Dysfunction; POCD
Interventions: Drug: Precedex (Dexmedetomidine); Drug: Placebo
Sponsors: Mount Sinai School of Medicine; Mount Sinai School of Medicine; National Institute on Aging (NIA)
Recruiting - verified January 2012 - Conditions: Extubation; Respiration Disorders
Intervention: Drug: Dexmedetomidine
Sponsors: University of California, San Francisco; University of California, San Francisco
Recruiting - verified October 2011 - Conditions: Preeclampsia; Hypotension
Interventions: Drug: Ephedrine; Drug: Phenylephrine
Sponsors: Northwestern University; Northwestern University
Recruiting - verified January 2012 - Conditions: Cocaine Abuse; Heroin Abuse
Interventions: Drug: Clonidine; Drug: Placebo
Sponsors: National Institutes of Health Clinical Center (CC); National Institute on Drug Abuse (NIDA)
Recruiting - verified September 2011 - Condition: Opioid-Related Disorders
Interventions: Drug: Clonidine; Drug: Placebo
Sponsors: National Institutes of Health Clinical Center (CC); National Institute on Drug Abuse (NIDA)
Recruiting - verified March 2012 - Conditions: Tachycardia; Chronic Orthostatic Intolerance
Interventions: Drug: Acetazolamide; Drug: Atomoxetine; Other: Baseline (No Drug); Drug: Clonidine; Drug: Entacapone; Drug: Entacapone & Propranolol; Drug: Atomoxetine & Propranolol; Drug: Indomethacin; Drug: Mecamylamine; Drug: Isosorbide Dinitrate; Dietary Supplement: Melatonin; Drug: Midodrine; Drug: Modafinil; Drug: Octreotide; Radiation: Placebo; Drug: Propranolol; Drug: Modafinil & Propranolol; Drug: Sertraline; Procedure: IV Saline; Other: Drinking Water; Device: Breathing Device; Drug: memantine; Device: Abdominal binder
Sponsors: Vanderbilt University; Satish R. Raj; National Institutes of Health (NIH)
Recruiting - verified February 2012 - Conditions: Autonomic Failure; Orthostatic Hypotension
Interventions: Drug: Atomoxetine; Drug: Acarbose; Drug: Pyridostigmine Bromide; Drug: Yohimbine; Drug: Midodrine HCl; Drug: placebo; Drug: Modafinil; Drug: Octreotide; Other: water intake; Drug: Diphenhydramine Hydrochloride; Drug: Ranitidine HCL; Drug: Tranylcypromine; Drug: Ergotamine/ Caffeine; Drug: Celecoxib; Drug: Pseudoephedrine; Drug: Methylphenidate; Drug: Indomethacin; Drug: Ibuprofen; Drug: Oxymetazoline 0.05% nasal solution; Dietary Supplement: Bovril; Drug: Acetazolamide; Drug: Rivastigmine tartrate; Drug: Carbidopa/levodopa; Device: abdominal binder; Device: abdominal binder (sham)
Sponsors: Vanderbilt University; Vanderbilt University
Recruiting - verified May 2012 - Condition: Hypertension
Interventions: Drug: Clonidine; Drug: Nitroglycerin transdermal; Drug: Dipyridamole/ Aspirin (Aggrenox); Drug: Desmopressin (DDAVP); Drug: Sildenafil; Drug: Nifedipine; Drug: Hydralazine; Drug: Hydrochlorothiazide; Drug: Placebo; Drug: Bosentan; Drug: Diltiazem; Drug: Eplerenone; Drug: guanfacine; Dietary Supplement: L-arginine; Drug: captopril; Drug: carbidopa; Drug: losartan; Drug: metoprolol tartrate; Drug: nebivolol hydrochloride; Drug: prazosin hydrochloride; Drug: tamsulosin hydrochloride; Other: Head-up tilt.
Sponsors: Vanderbilt University; Vanderbilt University
Recruiting - verified May 2012
 |
Adrenergic Alpha Agonists Clinical Trials |
